Compare PDD Holdings Inc. American Depositary Shares (PDD) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PDD Holdings Inc. American Depositary Shares vs TG Therapeutics Inc — how do they compare? PDD Holdings Inc. American Depositary Shares trades at $81.12 (market cap $111.40B), while TG Therapeutics Inc trades at $55.16 (market cap $8.16B). The key difference: PDD Holdings Inc. American Depositary Shares is far larger — about 13.7× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, PDD Holdings Inc. American Depositary Shares nearer its low. Which is the better fit depends on your goals.
| PDD | TGTX | |
|---|---|---|
Market Cap | $111.40B | $8.16B |
Volume | 4,823,275 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $138.13 | $59.06 |
52-Week Low | $73.30 | $26.94 |
Enterprise Value | $44.04B | $8.37B |
Typical Hold Time | — | 15 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About PDD Holdings Inc. American Depositary Shares
PDD Holdings is a multinational commerce group that owns and operates a portfolio of businesses. Its sourcing, logistics, and fulfillment network supports those businesses and their commerce operations.
Read more on PDD →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
